In a report issued on July 8, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on RedHill Biopharma (RDHL), with a price target of $16. The company’s shares closed yesterday at $6.65.
Ramakanth wrote:
“We maintain our Buy rating on RDHL and our 12-month price target of $16.00 per ADS. We derive our price target based on the average of two valuation methods: (1) price-sales multiple using 7x 2025 sales estimate discounted at 14%; and (2) price-earnings multiple analysis applying a 15x multiple to our 2025 estimated earnings also discounted at 14%. (1) commercial; (2) regulatory; (3) clinical; (4) partnership; (5) financial; and (6) intellectual property.”
According to TipRanks.com, Ramakanth is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -9.9% and a 30.7% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as IntelGenx Technologies, Gritstone Oncology Inc, and Trillium Therapeutics.
Currently, the analyst consensus on RedHill Biopharma is a Moderate Buy with an average price target of $19.50, implying a 193.2% upside from current levels. In a report issued on July 8, Ascendiant also maintained a Buy rating on the stock with a $23 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $11.49 and a one-year low of $5.13. Currently, RedHill Biopharma has an average volume of 57.21K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
RedHill Biopharma Ltd. is a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary drugs for the treatment of gastrointestinal diseases. It operates through two segments: Commercial Operations and Research & Development.
